scholarly journals New developments in the anti-neoplastic drug management of ovarian cancer

2013 ◽  
Vol 5 ◽  
Author(s):  
Maurie Markman
Keyword(s):  
Ovarian Cancer ◽  
Drug Management ◽  
New Developments

scholarly journals Current Ovarian Cancer Maintenance Strategies and Promising New Developments

2021 ◽  
Vol 12 (1) ◽  
pp. 38-53
Author(s):  
Vinaya Gogineni ◽  
Susan Morand ◽  
Hannah Staats ◽  
Rachel Royfman ◽  
Monika Devanaboyina ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
New Developments ◽  
Maintenance Strategies

scholarly journals New developments in the treatment of ovarian cancer—future perspectives

2013 ◽  
Vol 24 ◽  
pp. x69-x76 ◽  
Author(s):  
J. Lopez ◽  
S. Banerjee ◽  
S.B. Kaye
Keyword(s):  
Ovarian Cancer ◽  
Future Perspectives ◽  
New Developments

scholarly journals Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer

Cancers ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 191
Author(s):  
Adrianne Wallace-Povirk ◽  
Zhanjun Hou ◽  
Md. Junayed Nayeen ◽  
Aleem Gangjee ◽  
Larry H. Matherly
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Targeted Therapies ◽  
Folate Receptor ◽  
Gynecologic Malignancy ◽  
Folate Transport ◽  
New Developments ◽  
C1 Metabolism ◽  
Selective Delivery ◽  
One Carbon Metabolism

New therapies are urgently needed for epithelial ovarian cancer (EOC), the most lethal gynecologic malignancy. To identify new approaches for targeting EOC, metabolic vulnerabilities must be discovered and strategies for the selective delivery of therapeutic agents must be established. Folate receptor (FR) α and the proton-coupled folate transporter (PCFT) are expressed in the majority of EOCs. FRβ is expressed on tumor-associated macrophages, a major infiltrating immune population in EOC. One-carbon (C1) metabolism is partitioned between the cytosol and mitochondria and is important for the synthesis of nucleotides, amino acids, glutathione, and other critical metabolites. Novel inhibitors are being developed with the potential for therapeutic targeting of tumors via FRs and the PCFT, as well as for inhibiting C1 metabolism. In this review, we summarize these exciting new developments in targeted therapies for both tumors and the tumor microenvironment in EOC.

Sign in / Sign up

Export Citation Format

Share Document